SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)The suspension of trading in the securities of Lumos Diagnostics Holdings Limited will be lifted immediately following the release by LDX of an announcement regarding a strategic material agreement. | 16/07/2025 |
The company has signed a pivotal six-year exclusive U.S. distribution agreement with PHASE Scientific for FebriDx®, valued at up to $317 million. The agreement is subject to a CLIA waiver and includes a pre-paid purchase order and additional payment. | 16/07/2025 |
The company's securities will be suspended from quotation under Listing Rule 17.2 pending an announcement. The suspension will continue until the end of the requested period or the announcement's release. | 15/07/2025 |
The suspension of trading in the securities of Lumos Diagnostics Holdings Limited will be lifted immediately following the release by LDX of an announcement regarding a response to regulatory feedback received in relation to FebriDx. | 11/07/2022 |
The US FDA advised Lumos Diagnostics that, following its review of Lumos' 510(k) application, FebriDx did not demonstrate substantial equivalence to the predicate device and consequently has not been granted clearance for marketing in the U.S. The Company is currently reviewing the feedback provided by the FDA in order to determine the next steps. | 11/07/2022 |
The securities of Lumos Diagnostics Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of LDX, pending the release of an announcement regarding a response to regulatory feedback received in relation to FebriDx. | 08/07/2022 |
The suspension of trading in the options of Lumos Diagnostics Holdings Limited will be lifted immediately. | 01/07/2022 |
The company releases an Appendix 2A. | 30/06/2022 |
The options of Lumos Diagnostics Holdings Limited will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in LDX's Prospectus, announced to the market on 6 June 2022. The options are expected to be quoted on a normal settlement basis on Friday, 1 July 2022. The suspension only applies to the LDX's options (ASX: LDXO), and does not apply to any other quoted securities of LDX. | 24/06/2022 |
listed entity carried for record purposes only | 05/07/2021 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 11/06/2024 | Catherine Robson | 312,500 | $0.034 | $10,625.00 |
| 07/06/2024 | Sam Lanyon | 250,000 | $0.030 | $7,500.00 |
| 18/10/2023 | Doug Ward | 250,000 | $0.087 | $21,645.00 |
| 02/12/2022 | Catherine Robson | 208,332 | $0.049 | $10,269.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Sam Lanyon | Executive Chairman, Interim CEO | 05/07/2021 |
| Doug Ward | Managing Director, CEO | 21/06/2022 |
| Barrie Lambert | CFO | 16/02/2022 |
| Lawrence Mehren | Non Exec Director | 05/07/2021 |
| Catherine Robson | Non Exec Director | 05/07/2021 |
| Bronwyn Le Grice | Non Exec Director | 05/07/2021 |
| Tracy Weimar | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
